



# Oncology & Immuno- Oncology Expertise



**CellCarta**

Harnessing the power of biomarkers from discovery to late-stage clinical development and companion diagnostics (CDx)




# Setting the stage for the development of effective oncology therapies

Despite the numerous breakthroughs in cancer treatments, relapses and toxicities are grounds for careful investigation of targets, treatments, as well as stratification of patients to improve the efficacy and safety of therapies.

As biomarker experts, CellCarta helps you navigate the way with our complete services

and cross-platform approach designed to address your specific therapeutic development requirements. Our scientific team partners with you to harness the power of our immune monitoring, histopathology, proteomics, and genomics platforms.



Immune monitoring



Proteomics



Histopathology



Genomics

We provide you with highly customized solutions for **target discovery, pre-clinical and clinical testing**, with the capabilities to bring your program all the way to **companion diagnostics (CDx)**.

We support your project by ensuring the right level of validation is performed (exploratory, secondary, primary endpoints) and provide testing services for clinical trials that have the highest standard of quality (**CAP accredited, CLIA certified**).

## Excellence in range of clinical applications

Our team has a proven track record of success in the fields of oncology and immuno-oncology, having worked on all types of therapies: **cell and gene therapies, biologics, and small molecules**.

CAR T Therapies	Oncolytic viruses	Kinase Inhibitors
CAR NK Therapies	Antibody Drug Conjugates (ADCs)	Immune Checkpoint Inhibitors
TILs Therapies	Bi-specific Antibodies	Cancer Vaccines
Engineered TCRs	BiTEs	

**PARTNERING WITH YOU TO ACCELERATE THE APPROVAL OF YOUR CANCER TREATMENT AND IMPROVE HUMAN HEALTH.**

# Providing key biomarker insights for your oncology clinical trials

CellCarta provides biomarker strategies for all your clinical needs. From biomarkers to predict response and stratify patients, to solutions for a more detailed monitoring of the immune response following treatment, as well as tracking therapies and their status following treatment. Our bioanalysis expertise at CellCarta touches all types of samples, from tumor tissues, to biopsies, serum, plasma and more.

For **profiling of tumor samples**, CellCarta offers complete end-to-end solutions including protein biomarker analysis, sequencing, and overall assessment of tumor mutational burden. **Tumor infiltrating lymphocytes (TILs)** and all other cells present in the tumor microenvironment (TME) can also be fully characterized. We have the tools to investigate the **heterogeneity of tumors** by looking at the

single-cell level as well as monitor **circulating tumor cells**.

Before initiating treatment, molecular **profiling of therapeutic constructs** can be performed. Following treatment, some therapies warrant a cellular characterization to **monitor their presence and long-term viability**, all of which can be achieved with our assays customized to your therapy's specificities. Simple **pharmacokinetics** also allow for the monitoring of therapies.

**Monitoring of the patient response** can be performed through various bioanalysis. A patient's response can be investigated with an in-depth profiling of the **cellular immune response** and its **antigenic specificity**. Soluble markers and overall **cytokine profiles** also provide fair assessments of a patient's immune status.

## Striving to accelerate your success


Our **>20 years of expertise in oncology and immuno-oncology** combined with our unique, hands-on, highly scientific approach make us the ideal partner for your projects. Working as an extension of your lab, our team provides an **end-to-end service** to support you at every stage of your biomarker strategy.



### WORLDWIDE SAMPLE MANAGEMENT, KITTING & LOGISTICS SOLUTIONS

Our sample management & logistics expertise combined to our global presence allows us to fully support your international oncology programs, starting at the clinical site all the way to sample analysis.


**WHITE-GLOVE SERVICE FOR YOUR  
CRITICAL SPECIALTY SAMPLES**



### COLLABORATIVE ASSAY DESIGN AND DEVELOPMENT



### TIMELY CLINICAL SAMPLE TESTING



### DATA GENERATION SUPPORTED BY BIOINFORMATICS AND AI-DRIVEN SOLUTIONS

Access the most advanced data solutions with our proprietary software CellEngine™, a new generation of cytometry software.

Also benefit from an in-house bioinformatics team harnessing the power of AI-driven solutions and working in close collaboration with our scientists to help you navigate the large dataset often generated in oncology.



### BIOLOGICAL INTERPRETATION

# Global presence, local expertise



## ABOUT CELLCARTA

Leading provider of specialized precision medicine laboratory services to the biopharmaceutical industry. Leveraging its integrated analytical platforms in immunology, histopathology, proteomics and genomics, as well as related specimen collection and logistics services, CellCarta supports the entire drug development cycle, from discovery to late-stage clinical trials. The company operates globally with 10 facilities located in Canada, USA, Belgium, Australia, and China.

For more information on how CellCarta can partner with you, please contact us:

**[www.cellcarta.com](http://www.cellcarta.com)**

**[info@cellcarta.com](mailto:info@cellcarta.com)**

**Toll Free: + 1 877 776 3443**

## HEADQUARTERS

201 President Kennedy Ave., Suite 3900  
Montreal, Quebec, Canada H2X 3Y7  
Phone: + 1 514 360 3600



# CellCarta